NOT_YET_RECRUITING

Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Among those with hypertension, persons living with HIV (PWH) have a 50% higher risk of incident myocardial infarction compared to the general population, and they often fail to meet evidence-based treatment goals for hypertension. An important contributing factor for insufficient blood pressure control is non-adherence to antihypertensive medications. Research on medication adherence for PWH has largely focused on antiretroviral therapy adherence with limited focus on adherence to other non-AIDS condition medications. With a large proportion of PWH in the U.S. achieving viral suppression, providers may now have an opportunity to focus on the management of non-AIDS conditions like hypertension. However, because PWH who have achieved suppression have reduced clinic encounters (once or twice a year) there is potential loss of opportunity to effectively monitor and intensify hypertension treatment as needed an important opportunity to focus on preventing cardiovascular disease. CVD and other non-AIDS comorbidities. The study's overarching goal is to improve the hypertension outcomes for PWH on suppressive ART to reduce cardiovascular disease risk. In this study, we will identify and evaluate healthcare and patient-level factors that must be addressed in an intervention to increase hypertension medication adherence for PWH who have achieved viral suppression. We will use these factors to tailor an intervention and assess the feasibility and acceptability at the Duke ID clinic.

Official Title

Addressing Barriers to Anti-hypertensive Medication Adherence Among Persons Living With HIV Who Have Achieved Viral Suppression

Quick Facts

Study Start:2025-10-01
Study Completion:2026-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:NOT_YET_RECRUITING

Study ID

NCT05459077

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥18 years
  2. * Confirmed HIV+ diagnosis
  3. * Undetectable HIV viral load: defined as the most recent HIV viral load \<200 copies/mL checked within the past year (assessed via chart abstraction)
  4. * Hypertension diagnosis in medical records
  5. * Taking an antihypertensive medication
  6. * Receiving care at the Duke HIV clinic
  7. * HIV providers including infectious disease physicians, internists or advance practice practitioners who have a patient pool of PLWH under their care in the last 6 months.
  8. * Stakeholders composed of willing participants recruited from the Duke ID clinic and may include, HIV providers, clinic directors, nurses, pharmacists, social workers, people living with HIV who have hypertension and take antihypertensive medications, and representatives of the community advisory boards, and any other key stakeholders.
  9. * Age ≥18 years
  10. * Confirmed HIV+ diagnosis
  11. * Receiving care at the Duke ID clinic
  12. * Achievement of HIV suppression defined as having HIV-1 RNA \<200 copies/ml
  13. * Take antihypertensive medications
  14. * Uncontrolled BP over a 12 months period defined by participants with systolic BP\>130mmHg on ≥ 2 occasions in the past 12 months as indicated in the individual patient's electronic medical records
  1. * Severely hearing or speech impaired, or other disability that would limit participation in the intervention components
  2. * In a nursing home and/or receiving in-patient psychiatric care
  3. * Terminal illness with life expectancy \< 4 months
  4. * No reliable access to a telephone
  5. * Pregnant, breast-feeding, or planning a pregnancy during the study period
  6. * Planning to move out of the area in the next 6 months
  7. * Non-English speaking.

Contacts and Locations

Study Contact

Stuart T Carr, BA
CONTACT
919 668-4849
stuart.carr@duke.edu
Mersedes Brown, MPH
CONTACT
919 668-7364
mersedes.brown@duke.edu

Principal Investigator

Charles Muiruri, PhD
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Duke University

  • Charles Muiruri, PhD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-10-01
Study Completion Date2026-09-30

Study Record Updates

Study Start Date2025-10-01
Study Completion Date2026-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Hypertension
  • HIV-1-infection